Table 3.
Summary of dose used in studies
| Study | Treatment/median cycles (range) | Dose | Dose reduction or dose intensity | |||
|---|---|---|---|---|---|---|
| Anti-EGFR | L-OHP (mg/m2) | CPT-11 (mg/m2) | 5-FU (mg/m2) | |||
| C Garufi/2010 [14] | Cet+Chrono-IFLO/6 (3–15) | Cet (400mg/m2 initial, 250 weekly mg/m2) | 80 | 130 | 2400 |
L-OHP:60mg/m2 CPT-11:110mg/m2 5-FU:2200mg/m2 |
| Sougklakos, I./2011 [16] | Cet+FOLFOXIRI/NR | Cet 500mg/m2 | 65 | 150 | 600+400 (bolus) | NA |
| ERIC ASSENAT./2011 [17] | Cet+FOLFIRINOX/9 (1–12) | Cet (400 initial/250 weekly) | 85 | 180 | 2400+400 (bolus) | 76%required dose reduction, overall dose intensity was >90% |
| Z Saridaki/2012 [18] | Cet+FOLFOXIRI/12 (1–16) | Cet 500mg/m2 | 65 | 150 | 1200+400 (bolus) | NA |
| Folprecht, G./2013 | Cet+FOLFOXIRI/NR | Cet 500mg/m2 | 85 | 125 | 3200 | NA |
| Fornaro, L./2013 [20] | Pan+FOLFOXIRI/11 (3–16) | Pan 6mg/kg | 85 | 150 | 3000 | Relative dose intensity: L-OHP 75%, CPT-11 74%, 5-FU 76% |
| Bendell, J. C./2016 [21] | Pan+FOLFOXIRI/NA | Pan 6mg/kg | 85 | 125 | 3200 | NA |
| Pietrantonio, F/2017 [2017] | Cet+COI-E/NA | 500mg/m2 | 85 | 180 | 1000 twice d2-5b | NA |
| Cremolini, C./2018 [23] | Cet+FOLFOXIRI/8 (6–8) | Cet 500mg/m2 | 85 | 130 | 2400 | NA |
| D Modest/2019 [24] | Pan+FOLFOXIRI/11 (2–12) | Pan 6mg/kg | 85 | 165 | 3200 | NA |
| Ogata, T./2019 [25] |
Cet+FOLFOXIRI/7 (1–14) Pan+FOLFOXIRI/12 (9–12) |
Cet (400mg/m2 initial, 250 weekly mg/m2) | 85 | 125/150/165a | 3200 | NA |
| E. Samalin/2019 [26] | Cet+FOLFIRINOX/10 (2–12) | NA | NA | NA | NA | NA |
| Deng, Y./2020 | Cet+mFOLFOXIRI/7 (4–12) | Cet 500mg/m2 | 85 | 165 | 2800 | Relative dose intensity: L-OHP 96%, CPT-11 96%, 5-FU 96% |
| Akihito Tsuji/2021 [28] | Cet+mFOLFOXIRI/10 (1–12) | Cet 500mg/m2 | 85 | 150 | 2400 | NA |
aModified on UGT1A1 status; bcapecitabine; Cet, cetuximab; Pan, panitumumab; CPT-11, irinotecan; L-OHP, oxaliplatin; 5-FU, 5-fluorouracil; mFOLFOXIRI, modified FOLFOXIRI; COI-E, irinotecan+oxaliplatin+capecitabine; NA, not available